Molecular activity of BTK- and BCL2- inhibitors in CLL
Molecular activity of BTK- and BCL2- inhibitors in CLL. The interaction between the B cell receptor (BCR) and its antigen stimulates BTK activity through the SYK protein kinase and the BLNK adapter protein, resulting in the transcriptional activation of genes linked with B cell proliferation and survival. In CLL, the BCR signaling pathway is frequently hyperactivated. Consistently, BTK inhibitors impair this signaling cascade by binding covalently or non-covalently to BTK. On the other hand, the physiological role of the anti-apoptotic protein BCL2 is to sequester BAX, hampering its dimerization with BAK, resulting in heightened cell survival through the impairment of apoptosome formation. Cellular damage causes the inhibition of BCL2 through the BH3-only proteins, stimulating the formation of the BAX-BAK dimer, which promotes cellular death. In the context of CLL, BCL2 is frequently found to be overexpressed, and, for this reason, the BH3 mimetic venetoclax is used to hamper BCL2 activity, resulting in the induction of apoptosis. Abbreviations: SYK, spleen tyrosine kinase; BLNK, B-cell linker; BTK, Bruton tyrosine kinase; PIP3, phosphatidylinositol 3,4,5-trisphosphate; PI3Kδ, phosphoinositide 3-kinase delta; PIP2, phosphatidylinositol 4,5-bisphosphate; PLCγ2, phospholipase C gamma 2; IP3, inositol trisphosphate, DAG, diglyceride; PKCβ, protein kinase C beta; CaM, calmodulin; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; ERK, extracellular signal-regulated kinases; NFAT, nuclear factor of activated T-cells; BCL2, B cell lymphoma 2; BH3, BCL2 homology 3; BAX, BCL2-associated X protein; BAK, BCL2 homologous antagonist/killer. Created with BioRender.com (accessed on: 29 October 2023)